Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurotherapeutics
Published in: Neurotherapeutics 1/2016

01-01-2016 | Review

Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis

Authors: Jens Ingwersen, Orhan Aktas, Hans-Peter Hartung

Published in: Neurotherapeutics | Issue 1/2016

Login to get access

Abstract

Treatment options in relapsing-remitting multiple sclerosis have increased considerably in recent years; currently, a dozen different preparations of disease-modifying therapies are available and some more are expected to be marketed soon. For the treating neurologist this broad therapeutic repertoire not only greatly improves individualized management of the disease, but also makes choices more complex and difficult. A number of factors must be considered, including disease activity and severity, safety profile, and patient preference. We here discuss the currently existing options and suggest treatment algorithms for managing relapsing-remitting multiple sclerosis.
Appendix
Available only for authorised users
Literature
1.
Oh J, O'Connor PW. Novel and imminently emerging treatments in relapsing-remitting multiple sclerosis. Curr Opin Neurol 2015;28:230-236.CrossRefPubMed
2.
3.
Duquette P, Girard M, Despault L. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993;43:655-661.CrossRef
4.
Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294.CrossRefPubMed
5.
PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498-1504.CrossRef
6.
Calabresi PA, Kieseier BC, Arnold DL, et al. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 2014;13:657-665.CrossRefPubMed
7.
Koch-Henriksen N, Sørensen PS, Christensen T, et al. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 2006;66:1056-1060.CrossRefPubMed
8.
Kieseier BC. The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS Drugs 2011;25:491-502.CrossRefPubMed
9.
Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-1276.CrossRefPubMed
10.
Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol 2013;73:705-713.CrossRefPubMed
11.
Aharoni R. Immunomodulation neuroprotection and remyelination—the fundamental therapeutic effects of glatiramer acetate: a critical review. J Autoimmun 2014;54:81-92.CrossRefPubMed
12.
Edgar CM, Brunet DG, Fenton P, McBride EV, Green P. Lipoatrophy in patients with multiple sclerosis on glatiramer acetate. Can J Neurol Sci 2004;31:58-63.CrossRefPubMed
13.
Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology 2012;79:1130-1135.CrossRefPubMedPubMedCentral
14.
Linker RA, Lee D, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011;134:678-692.CrossRefPubMed
15.
Scannevin RH, Chollate S, Jung M, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther 2012;341:274-284.CrossRefPubMed
16.
Chen H, Assmann JC, Krenz A, et al. Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE. J Clin Invest 2014;124:2188-2192.CrossRefPubMed
17.
Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-1107.CrossRefPubMed
18.
Viglietta V, Miller D, Bar-Or A, et al. Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. Ann Clin Transl Neurol 2015;2:103-118.CrossRefPubMed
19.
Miller DH, Fox RJ, Phillips JT, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology 2015;84:1145-1152.CrossRefPubMedPubMedCentral
20.
Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-1097.CrossRefPubMed
21.
Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med 2013;368:1657-1658.CrossRefPubMed
22.
van Oosten, Bob W, Killestein J, Barkhof F, Polman CH, Wattjes MP. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 2013;368:1658-1659.CrossRefPubMed
23.
Rosenkranz T, Novas M, Terborg C. PML in a patient with lymphocytopenia treated with dimethyl fumarate. N Engl J Med 2015;372:1476-1478.CrossRefPubMed
24.
Nieuwkamp DJ, Murk J, van Oosten, et al. PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. N Engl J Med 2015;372:1474-1476.CrossRefPubMed
25.
Dubey D, Kieseier BC, Hartung HP, et al. Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety. Expert Rev Neurother 2015;15:339-346.CrossRefPubMed
26.
Sheremata W, Brown AD, Rammohan KW. Dimethyl fumarate for treating relapsing multiple sclerosis. Expert Opin Drug Saf 2015;14:161-170.CrossRefPubMed
27.
Osiri M, Shea B, Robinson V, et al. Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev 2003:CD002047.
28.
Claussen MC, Korn T. Immune mechanisms of new therapeutic strategies in MS: teriflunomide. Clin Immunol 2012;142:49-56.CrossRefPubMed
29.
Fairbanks LD, Bofill M, Ruckemann K, Simmonds HA. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J Biol Chem 1995;270:29682-29689.CrossRefPubMed
30.
O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365:1293-1303.CrossRefPubMed
31.
Confavreux C, O'Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:247-256.CrossRefPubMed
32.
Vermersch P, Czlonkowska A, Grimaldi, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler 2014;20:705-716.CrossRefPubMed
33.
Warnatz K, Peter HH, Schumacher M, et al. Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature. Ann Rheum Dis 2003;62:50-57.CrossRefPubMedPubMedCentral
34.
Rahmlow M, Shuster EA, Dominik J, et al. Leflunomide-associated progressive multifocal leukoencephalopathy. Arch Neurol 2008;65:1538-1539.CrossRefPubMed
35.
Schmedt N, Andersohn F, Garbe E. Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf 2012;21:1216-1220.CrossRefPubMed
36.
Kieseier BC, Benamor M. Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis. Neurol Ther 2014;3:133-138.CrossRefPubMedPubMedCentral
37.
Sartori A, Carle D, Freedman MS. Teriflunomide: a novel oral treatment for relapsing multiple sclerosis. Expert Opin Pharmacother 2014;15:1019-1027.CrossRefPubMed
38.
Ingwersen J, Aktas O, Kuery P, Kieseier B, Boyko A, Hartung H. Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy. Clin Immunol 2012;142:15-24.CrossRefPubMed
39.
Prager B, Spampinato SF, Ransohoff RM. Sphingosine 1-phosphate signaling at the blood-brain barrier. Trends Mol Med 2015;21:354-363.CrossRefPubMed
40.
Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008;63:61-71.CrossRefPubMed
41.
Choi JW, Gardell SE, Herr DR, et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci U S A 2011;108:751-756.CrossRefPubMed
42.
Kim HJ, Miron VE, Dukala D, et al. Neurobiological effects of sphingosine 1-phosphate receptor modulation in the cuprizone model. FASEB J 2011;25:1509-1518.CrossRefPubMedPubMedCentral
43.
Lublin F, Miller D, Freedman M, et al. Oral fingolimod versus placebo in primary progressive multiple sclerosis: results of INFORMS, a large phase III, randomized, double-blind, placebo-controlled trial. Lancet 2016 (in press).
44.
Kappos L, Radue E, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.CrossRefPubMed
45.
Calabresi PA, Radue E, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:545-556.CrossRefPubMed
46.
Devonshire V, Havrdova E, Radue EW, et al. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol 2012;11:420-428.CrossRefPubMed
47.
Radue E, O'Connor P, Polman CH, et al. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Arch Neurol 2012;69:1259-1269.CrossRefPubMed
48.
Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-415.CrossRefPubMed
49.
Bergvall N, Makin C, Lahoz R, et al. Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study. PLoS ONE 2014;9:e88472.CrossRefPubMedPubMedCentral
50.
Nixon R, Bergvall N, Tomic D, Sfikas N, Cutter G, Giovannoni G. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis. Adv Ther 2014;31:1134-1154.CrossRefPubMedPubMedCentral
51.
Kalincik T, Horakova D, Spelman T, et al. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Ann Neurol 2015;77:425-435.CrossRefPubMed
52.
Huang D. Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod. Neurology 2015; 85:1001-1003.CrossRefPubMed
53.
Arvin AM, Wolinsky JS, Kappos L, et al. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol 2015;72:31-39.CrossRefPubMed
54.
55.
Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.CrossRefPubMed
56.
Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-381.CrossRefPubMed
57.
Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-374.CrossRefPubMed
58.
Butzkueven H, Kappos L, Pellegrini F, et al. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatr 2014;85:1190-1197.CrossRefPubMed
59.
Aktas O. Natalizumab in clinical practice: managing the risks, enjoying the benefits. J Neurol Neurosurg Psychiatr 2014;85:1181.CrossRefPubMed
60.
Spelman T, Kalincik T, Zhang A, et al. Comparative efficacy of switching to natalizumab in active multiple sclerosis. Ann Clin Transl Neurol 2015;2:373-387.CrossRefPubMedPubMedCentral
61.
62.
Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870-1880.CrossRefPubMed
63.
Fine AJ, Sorbello A, Kortepeter C, Scarazzini L. Progressive multifocal leukoencephalopathy after natalizumab discontinuation. Ann Neurol 2014;75:108-115.CrossRefPubMed
64.
Wattjes MP, Killestein J. Progressive multifocal leukoencephalopathy after natalizumab discontinuation: few and true? Ann Neurol 2014;75:462.CrossRefPubMed
65.
Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014;76:802-812.CrossRefPubMed
66.
Schwab N, Schneider-Hohendorf T, Posevitz V, et al. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology 2013;81:865-871.CrossRefPubMed
67.
Villar LM, Costa-Frossard L, Masterman T, et al. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. Ann Neurol 2015;77:447-457.CrossRefPubMed
68.
Warnke C, von Geldern G, Markwerth P, et al. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014;76:792-801.CrossRefPubMedPubMedCentral
69.
Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1819-1828.CrossRefPubMed
70.
Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829-1839.CrossRefPubMed
71.
Havrdova E, Horakova D, Kovarova I. Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Ther Adv Neurol Disord 2015;8:31-45.CrossRefPubMedPubMedCentral
72.
Waggoner J, Martinu T, Palmer SM. Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. J Heart Lung Transplant 2009;28:395-398.CrossRefPubMedPubMedCentral
73.
Isidoro L, Pires P, Rito L, Cordeiro G. Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab. BMJ Case Rep 2014;2014.
74.
Rau D, Lang M, Harth A, et al. Listeria meningitis complicating alemtuzumab treatment in multiple sclerosis-report of two cases. Int J Mol Sci 2015;16:14669-14676.CrossRefPubMedPubMedCentral
75.
76.
77.
Menge T, Stüve O, Kieseier BC, Hartung H. Alemtuzumab: the advantages and challenges of a novel therapy in MS. Neurology 2014;83:87-97.CrossRefPubMed
78.
McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.CrossRefPubMed
79.
Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-846.CrossRefPubMed
80.
Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.CrossRefPubMedPubMedCentral
81.
Klawiter EC, Cross AH, Naismith RT. The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%? Neurology 2009;73:984-990.CrossRefPubMedPubMedCentral
82.
Baldwin KJ, Hogg JP. Progressive multifocal leukoencephalopathy in patients with multiple sclerosis. Curr Opin Neurol 2013;26:318-323.CrossRefPubMed
83.
Warnke C, Olsson T, Hartung H. PML: The dark side of immunotherapy in multiple sclerosis. Trends Pharmacol Sci 2015.
84.
Chahin S, Berger JR. A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy. J Neurovirol 2015;21:623-631.CrossRefPubMed
85.
Faulkner M. Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis. Expert Opin Drug Saf 2015;14:1737-1748.CrossRefPubMed
86.
Wattjes MP, Barkhof F. Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. Curr Opin Neurol 2014;27:260-270.CrossRefPubMed
87.
McGuigan C, Craner M, Guadagno J, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatr 2015 (in press).
88.
89.
90.
Stüve O, Centonze D. Treatment decisions for patients with active multiple sclerosis. JAMA Neurol 2015;72:387-389.CrossRefPubMed
91.
Río J, Castilló J, Rovira A, et al. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 2009;15:848-853.CrossRefPubMed
92.
Sormani MP, Rio J, Tintorè M, et al. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler 2013;19:605-612.CrossRefPubMed
93.
Sormani M, Signori A, Stromillo M, de Stefano N. Refining response to treatment as defined by the Modified Rio Score. Mult Scler 2013;19:1246-1247.CrossRefPubMed
94.
Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009;8:254-260.CrossRefPubMed
95.
Bevan CJ, Cree, Bruce A C. Disease activity free status: a new end point for a new era in multiple sclerosis clinical research? JAMA Neurol 2014;71:269-270.CrossRefPubMed
96.
Hauser SL, Chan JR, Oksenberg JR. Multiple sclerosis: Prospects and promise. Ann Neurol 2013;74:317-327.CrossRefPubMed
97.
Mancardi GL, Sormani MP, Gualandi F, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology 2015;84:981-988.CrossRefPubMed
98.
Iaffaldano P, Lucisano G, Pozzilli C, et al. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain 2015;138:3275-3286.CrossRefPubMed
99.
Cohen M, Maillart E, Tourbah A, et al. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. JAMA Neurol 2014;71:436-441.CrossRefPubMed
100.
Hoepner R, Havla J, Eienbröker C, et al. Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod. Mult Scler 2014;20:1714-1720.CrossRefPubMed
101.
102.
Rush CA, MacLean HJ, Freedman MS. Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol 2015;11:379-389.CrossRefPubMed
103.
Clanet MC, Wolinsky JS, Ashton RJ, Hartung H, Reingold SC. Risk evaluation and monitoring in multiple sclerosis therapeutics. Mult Scler 2014;20:1306-1311.CrossRefPubMedPubMedCentral
104.
Lublin FD, Cofield SS, Cutter GR, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol 2013;73:327-340.CrossRefPubMedPubMedCentral
105.
Cadavid D, Balcer L, Galetta S, et al. Efficacy Analysis of the Anti-LINGO-1 Monoclonal Antibody BIIB033 in Acute Optic Neuritis: the RENEW Trial (P7. 202). Neurology 2015;84(Suppl. 14).
106.
Aktas O, Vanopdenbosch L, Comi G, et al. Anti-LINGO-1 monoclonal antibody BIIB033 improves optic nerve latency in acute optic neuritis: primary efficacy analysis of the RENEW study. ECTRIMS Online Library 2015:116669.
107.
Metadata
Title
Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis
Authors
Jens Ingwersen
Orhan Aktas
Hans-Peter Hartung
Publication date
01-01-2016
Publisher
Springer US
Published in
Neurotherapeutics / Issue 1/2016
Print ISSN: 1933-7213
Electronic ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-015-0412-4

Other articles of this Issue 1/2016

Neurotherapeutics 1/2016 Go to the issue

Review

Efficacy of Intravenous Immunoglobulin in Neurological Diseases

Review

Antibody-Mediated Autoimmune Encephalopathies and Immunotherapies

Original Article

Chronic Treatment with the AMPK Agonist AICAR Prevents Skeletal Muscle Pathology but Fails to Improve Clinical Outcome in a Mouse Model of Severe Spinal Muscular Atrophy

Editorial

Neuro-Immunotherapies: A 30-year Retrospective of an Overwhelming Success and a Brighter Future

Review

Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis

Review

Immunotherapies for Immune-Mediated Myopathies: A Current Perspective